الإحصائيات الأساسية
| CIK | 1561921 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TELA Bio, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 11, 2025 |
Calculation of Filing Fee Tables S-8 TELA Bio, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share 457(a) 3,500,000 $ 1.74 $ 6,090,000.00 0.0001531 $ 932.38 Total Offering Amou |
|
| August 11, 2025 |
INVESTOR PRESENTATION August 2025 Exhibit 99.2 INVESTOR PRESENTATION August 2025 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assu med future results of operations, business strategies, development p |
|
| August 11, 2025 |
Amendment No. 1 to TELA Bio, Inc. Amended & Restated 2019 Equity Incentive Plan (filed herewith). Exhibit 10.1 TELA BIO, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN WHEREAS, the Board of Directors of TELA Bio, Inc., a Delaware corporation (the “Company”) approved and adopted the Amended and Restated 2019 Equity Incentive Plan (the “2019 Plan”) of the Company on April 20, 2020; and WHEREAS, the Board of Directors and the stockholders of the Company have determined th |
|
| August 11, 2025 |
TELA Bio Reports Second Quarter 2025 Financial Results Exhibit 99.1 TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, PA, August 11, 2025 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights · Delivered revenue of $20.2 million in the second quarter 20 |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 11, 2025 |
As filed with the United States Securities and Exchange Commission on August 11, 2025 As filed with the United States Securities and Exchange Commission on August 11, 2025 Registration No. |
|
| August 11, 2025 |
Amendment No. 1 to TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan. Exhibit 99.2 TELA BIO, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN WHEREAS, the Board of Directors of TELA Bio, Inc., a Delaware corporation (the “Company”) approved and adopted the Amended and Restated 2019 Equity Incentive Plan (the “2019 Plan”) of the Company on April 20, 2020; and WHEREAS, the Board of Directors and the stockholders of the Company have determined th |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 11, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF TELA BIO, INC. TELA Bio, Inc. (the “Corporation”), a corporation organized and existing under the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: 1. The name of this corporation is TELA Bio, Inc. The Corporation’s original Certificate of Incorporation was filed with t |
|
| August 11, 2025 |
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”), dated June 2, 2025, is made and entered into by and between TELA BIO, INC., a Delaware corporation (the “Company”), and JEFFREY BLIZARD (the “Executive”). WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set forth herein. NOW, THEREFORE, i |
|
| June 2, 2025 |
Exhibit 99.1 TELA Bio Appoints Jeffrey Blizard as President Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, PA – June 2, 2025 – TELA Bio, Inc. ("TELA Bio") a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effect |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 8, 2025 |
INVESTOR PRESENTATION May 2025 Exhibit 99.2 INVESTOR PRESENTATION May 2025 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assu med future results of operations, business strategies, development plan |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 8, 2025 |
TELA Bio Reports First Quarter 2025 Financial Results Exhibit 99.1 TELA Bio Reports First Quarter 2025 Financial Results MALVERN, PA, May 8, 2025 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights ● Delivered revenue of $18.5 million in the first quarter 2025, re |
|
| April 17, 2025 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 17, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 7, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 31, 2025 |
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex Exhibit 99.1 TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue rec |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 21, 2025 |
Subsidiaries of the Registrant (filed herewith). Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary Ownership Percentage Jurisdiction of Incorporation or Organization TELA Bio, Limited 100% England and Wales TELA Bio GmbH 100% by TELA Bio, Limited Berlin |
|
| March 21, 2025 |
TELA Bio, Inc. Amended and Restated Non-Employee Director Compensation Policy (filed herewith). Exhibit 10.18 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Non-employee members of the board of directors (the “Board”) of TELA Bio, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy shall be pa |
|
| March 21, 2025 |
TELA Bio, Inc. Insider Trading Policy (filed herewith). Exhibit 19.1 TELA BIO, INC. INSIDER TRADING POLICY Effective February 23, 2023 I.Purpose TELA Bio, Inc. (the “Company”) has adopted this Insider Trading Policy (this “Policy”) to satisfy the Company’s obligation to prevent insider trading and to help the Company’s personnel and its external advisors avoid violating insider trading laws. II.Persons Subject to the Policy This Policy applies to (i) a |
|
| March 21, 2025 |
As filed with the United States Securities and Exchange Commission on March 21, 2025 As filed with the United States Securities and Exchange Commission on March 21, 2025 Registration No. |
|
| March 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) TELA Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value pe |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 20, 2025 |
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, PA, March 20, 2025 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights · Delivered revenue of $17.6 m |
|
| March 20, 2025 |
INVESTOR PRESENTATION March 2025 Exhibit 99.2 INVESTOR PRESENTATION March 2025 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assu med future results of operations, business strategies, development pl |
|
| February 13, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EX-99.1 AGREEMENT 2 tela13ga1.htm EXHIBIT 99 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 19 |
|
| November 14, 2024 |
TELA / TELA Bio, Inc. / LYTTON LAURENCE W Passive Investment SC 13G/A 1 tela13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TELA Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 872381108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 8, 2024 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ADDENDUM TO THE SECOND AMENDED AND RESTATED LICENSE, PRODUCT DEVELOPMENT AND SUPPLY UMBRELLA AGREEMENT This Addendum to the Second Amended and Restated Licens |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 7, 2024 |
INVESTOR PRESENTATION November 2024 Exhibit 99.2 INVESTOR PRESENTATION November 2024 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, busin |
|
| November 7, 2024 |
Exhibit 99.1 TELA Bio Reports Third Quarter 2024 Financial Results Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 MALVERN, PA, November 7, 2024 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported fi |
|
| October 29, 2024 |
TELA / TELA Bio, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G 1 tela13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TELA Bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 872381108 (CUSIP Number) October 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| October 28, 2024 |
TELA / TELA Bio, Inc. / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d856443dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TELA Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Fund 2, L.P. 21 Waterway Avenue, Suite 225 The |
|
| October 25, 2024 |
TELA / TELA Bio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment SC 13D/A 1 ss4036576sc13da.htm AMENDMENT NO. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* TELA Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 872381108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telepho |
|
| October 25, 2024 |
EX-99.1 2 ss4036576ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 6 to the Statement on Schedule 13D, dated October 23, 2024, with respect to the common stock of TELA Bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. |
|
| October 23, 2024 |
Exhibit 4.1 TELA BIO, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2024 TELA Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitled, subject to |
|
| October 23, 2024 |
Exhibit 1.1 Execution Version 12,000,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 5,800,000 Shares of Common Stock TELA Bio, Inc. UNDERWRITING AGREEMENT October 23, 2024 CANACCORD GENUITY LLC As Representative of the several Underwriters listed in Schedule A thereto One Post Office Square, Suite 3000 Boston, MA 02109 Ladies and Gentlemen: Introductory. TELA Bio, Inc., a Delaware |
|
| October 23, 2024 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-275511 PROSPECTUS SUPPLEMENT (To Prospectus dated November 20, 2023) TELA Bio, Inc. 12,000,000 Shares of Common Stock Pre-funded Warrants to Purchase 5,800,000 Shares of Common Stock We are offering 12,000,000 shares of our common stock, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 22, 2024 |
SUBJECT TO COMPLETION, DATED OCTOBER 22, 2024. TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| October 22, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 1, 2024 |
EX-99.1 2 ss3937845ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated September 27, 2024 (the “Statement”), with respect to the ordinary shares of TELA Bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amend |
|
| October 1, 2024 |
TELA / TELA Bio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* TELA Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 872381108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 13, 2024 |
Letter Agreement, dated May 20, 2024, by and between TELA Bio, Inc. and Greg Firestone. Exhibit 10.1 May 20, 2024 Re:Promotion to Chief Commercial Officer Dear Greg: This letter serves to memorialize your agreement with TELA Bio, Inc. (the “Company”) regarding certain compensation-related matters relating to your Employment Agreement and, in certain cases, during the Promotion Period (each, as defined below). Capitalized terms used but not otherwise defined herein shall have the mean |
|
| August 12, 2024 |
INVESTOR PRESENTATION August 2024 Exhibit 99.2 INVESTOR PRESENTATION August 2024 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, busines |
|
| August 12, 2024 |
Exhibit 99.1 TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance MALVERN, PA, August 12, 2024 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. Recent Highlights · Reported reve |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 22, 2024 |
TELA / TELA Bio, Inc. / LYTTON LAURENCE W Passive Investment SC 13G 1 tela13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TELA Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 872381108 (CUSIP Number) July 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| July 2, 2024 |
EX-99.1 2 ss3585186ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated July 2, 2024 (the “Statement”), with respect to the ordinary shares of TELA Bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Ea |
|
| July 2, 2024 |
TELA / TELA Bio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment SC 13D/A 1 ss3585186sc13da.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* TELA Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 872381108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telepho |
|
| June 10, 2024 |
SC 13G/A 1 tela-sc13ga053124.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment) TELA Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 872381108 (CUSIP Number) May 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| June 6, 2024 |
TELA Bio Appoints Jeffrey Blizard to its Board of Directors Exhibit 99.1 TELA Bio Appoints Jeffrey Blizard to its Board of Directors MALVERN, Pa., June 4, 2024, (GLOBE NEWSWIRE) - TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device t |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 20, 2024 |
TELA Bio Appoints Greg Firestone as Chief Commercial Officer Exhibit 99.1 TELA Bio Appoints Greg Firestone as Chief Commercial Officer MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) - TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company’s new Chief Commercial Officer. In this role, Mr. Firestone will ove |
|
| May 20, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2024 |
INVESTOR PRESENTATION May 2024 Exhibit 99.2 INVESTOR PRESENTATION May 2024 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, business s |
|
| May 9, 2024 |
TELA Bio Reports First Quarter 2024 Financial Results Exhibit 99.1 TELA Bio Reports First Quarter 2024 Financial Results MALVERN, PA, May 9, 2024 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights · Reported revenue of $16.6 million in the first quarter, represent |
|
| April 18, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 18, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 15, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 15, 2024 |
Exhibit 99.1 TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) - TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focu |
|
| March 22, 2024 |
TELA Bio, Inc. Amended and Restated Non-Employee Director Compensation Policy (filed herewith). Exhibit 10.18 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Non-employee members of the board of directors (the “Board”) of TELA Bio, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy shall be pa |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 22, 2024 |
Exhibit 10.36 FOURTH AMENDMENT TO LEASE AGREEMENT THIS FOURTH AMENDMENT TO LEASE AGREEMENT (this “Fourth Amendment”) is made this 18th day of October, 2023 (the “Effective Date”), by and between WPT LAND 2 LP, a Delaware limited partnership (“Landlord”), and TELA BIO, INC., a Delaware corporation (“Tenant”). BACKGROUND: A.Landlord (pursuant to that certain Assignment and Assumption of Leases dated |
|
| March 22, 2024 |
Exhibit 10.31 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ADDENDUM TO THE SECOND AMENDED AND RESTATED LICENSE, PRODUCT DEVELOPMENT AND SUPPLY UMBRELLA AGREEMENT This Addendum to the Second Amended and Restated Licen |
|
| March 22, 2024 |
As filed with the United States Securities and Exchange Commission on March 22, 2024 As filed with the United States Securities and Exchange Commission on March 22, 2024 Registration No. |
|
| March 22, 2024 |
Subsidiaries of the Registrant (filed herewith). Exhibit 21.1 LIST OF SUBSIDIARIES Jurisdiction of Incorporation or Subsidiary Ownership Percentage Organization TELA Bio, Limited 100% England and Wales |
|
| March 22, 2024 |
TELA Bio, Inc. Compensation Recovery Policy (filed herewith). Exhibit 97.1 TELA BIO, INC. COMPENSATION RECOVERY POLICY Adopted as of November 8, 2023 TELA Bio, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) |
|
| March 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) TELA Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value pe |
|
| March 22, 2024 |
Exhibit 10.25 Execution Version AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as October 18, 2023, by and among TELA BIO, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the other financial institutions or other en |
|
| March 21, 2024 |
Exhibit 99.1 TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results MALVERN, PA, March 21, 2024 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anat |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 21, 2024 |
INVESTOR PRESENTATION March 2024 Exhibit 99.2 INVESTOR PRESENTATION March 2024 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, business |
|
| March 21, 2024 |
Exhibit 99.3 TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue. MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) - TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused o |
|
| March 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 20, 2024 |
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX Exhibit 99.1 TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX TELA Bio to receive at least $8 million and up to $12 million in total consideration. MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) - TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the sale o |
|
| February 14, 2024 |
TELA / TELA Bio, Inc. / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13G Passive Investment SC 13G 1 d756347dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tela Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Acquisition Fund, L.P. 21 Waterway Avenue, Suite 225 The Woodlands |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* TELA Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 872381108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 7, 2024 |
TELA / TELA Bio, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 TELA Bio, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 872381108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 16, 2023 |
TELA Bio, Inc. 1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania 19355 November 16, 2023 TELA Bio, Inc. 1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania 19355 November 16, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Re: TELA Bio, Inc. Registration Statement on Form S-3 SEC File No. 333-275511 Filed November 13, 2023 Ladies and Gentlemen: Pu |
|
| November 13, 2023 |
Exhibit 1.2 EXECUTION VERSION TELA Bio, Inc. EQUITY DISTRIBUTION AGREEMENT November 13, 2023 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), TELA Bio, Inc., a company organized under the laws of the State of Delaware (the “Company”), proposes to issue and sell from time to time t |
|
| November 13, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) TELA Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registr |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 13, 2023 |
Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF TELA BIO, INC. (the “Corporation”) Adopted and effective as of November 8, 2023 ARTICLE I Stockholders Section 1.1.Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Corporati |
|
| November 13, 2023 |
Form of Indenture (filed herewith). Exhibit 4.4 TELA BIO, INC. INDENTURE Dated as of , 20 [ ] as Trustee Table of Contents Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of Te |
|
| November 13, 2023 |
Exhibit 10.2 EXECUTION VERSION TELA Bio, Inc. EQUITY DISTRIBUTION AGREEMENT November 13, 2023 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), TELA Bio, Inc., a company organized under the laws of the State of Delaware (the “Company”), proposes to issue and sell from time to time |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 9, 2023 |
TELA Bio Reports Third Quarter 2023 Financial Results Exhibit 99.1 TELA Bio Reports Third Quarter 2023 Financial Results MALVERN, PA, November 9, 2023 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the third |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 9, 2023 |
INVESTOR PRESENTATION November 2023 Exhibit 99.2 INVESTOR PRESENTATION November 2023 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, busin |
|
| October 20, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 6, 2023 |
EX-99.A 2 ex-a.htm JOINT FILING AGREEMENT Exhibit a CUSIP No . 872381108 Page 7 of 7 Exhibit A JOINT FILING AGREEMENT The Undersigned agree that the statement on Schedule 13G with respect to the common stock of TELA Bio, Inc. dated as of October 6, 2023, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* TELA Bio, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 872381108 (CUSIP Number) September 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 16, 2023 |
Exhibit 99.1 TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery New addition expands reconstruction options for surgeons and patients MALVERN, PA., August 16, 2023 – TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical |
|
| August 10, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”), dated as of August 3, 2023, is made and entered into by and between TELA Bio, Inc., a Delaware corporation (the “Company”), and Gregory Firestone (the “Executive”). WHEREAS, the Company and Executive desire to continue the employment of Executive with the Company, on the terms and conditions set forth herein. NOW, THERE |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 9, 2023 |
TELA Bio Reports Second Quarter 2023 Financial Results Exhibit 99.1 TELA Bio Reports Second Quarter 2023 Financial Results MALVERN, PA, August 9, 2023 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the second |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 9, 2023 |
INVESTOR PRESENTATION August 2023 Exhibit 99.2 INVESTOR PRESENTATION August 2023 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, busines |
|
| June 2, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 11, 2023 |
TELA Bio Reports First Quarter 2023 Financial Results Exhibit 99.1 TELA Bio Reports First Quarter 2023 Financial Results MALVERN, PA, May 11, 2023 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the first qua |
|
| May 11, 2023 |
INVESTOR PRESENTATION May 2023 EX-99.2 3 tm2315327d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 INVESTOR PRESENTATION May 2023 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assu |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 21, 2023 |
TELA / TELA Bio Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* TELA Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 872381108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone |
|
| April 21, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated April 19, 2023 (the “Statement”), with respect to the ordinary shares of TELA Bio, Inc. |
|
| April 20, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 20, 2023 |
Exhibit 1.1 Execution Version 4,750,000 Shares TELA Bio, Inc. Common Stock UNDERWRITING AGREEMENT April 18, 2023 JEFFERIES LLC PIPER SANDLER & CO. LAKE STREET CAPITAL MARKETS, LLC As Representatives of the several Underwriters listed in Schedule A thereto c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 1251 Avenue of the Americas, 6th Floor New York, New York |
|
| April 20, 2023 |
4,750,000 Shares TELA Bio, Inc. Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-251505 PROSPECTUS SUPPLEMENT (To Prospectus dated December 29, 2020) 4,750,000 Shares TELA Bio, Inc. Common Stock We are offering 4,750,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “TELA.” On April 17, 2023, the last reported sale price of our common stock on The Nas |
|
| April 18, 2023 |
SUBJECT TO COMPLETION, DATED APRIL 18, 2023. TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| April 18, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 17, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 17, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 23, 2023 |
Subsidiaries of the Registrant (filed herewith). EX-21.1 7 tela-20221231xex21d1.htm EX-21.1 Exhibit 21.1 LIST OF SUBSIDIARIES Jurisdiction of Incorporation or Subsidiary Ownership Percentage Organization TELA Bio, Limited 100% England and Wales |
|
| March 23, 2023 |
Amendment No. 1 to TELA Bio, Inc. 2019 Employee Stock Purchase Plan (filed herewith). Exhibit 10.15 First Amendment to TELA Bio, Inc. 2019 Employee Stock Purchase Plan WHEREAS, TELA Bio, Inc., a Delaware Corporation (the “Company”) sponsors the TELA Bio, Inc. 2019 Employee Stock Purchase Plan (the “Plan”); WHEREAS, pursuant to Section 19.8 of the Plan, the Compensation Committee of the Board of Directors of the Company (the “Committee”) may, in its sole discretion, amend the Plan a |
|
| March 23, 2023 |
TELA Bio, Inc. Amended and Restated Non-Employee Director Compensation Policy (filed herewith). Exhibit 10.18 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Non-employee members of the board of directors (the “Board”) of TELA Bio, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy shall be pa |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 23, 2023 |
Exhibit 10.13 TELA BIO, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE AND PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT TELA Bio, Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 2019 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an award of the target numb |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) TELA Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value pe |
|
| March 23, 2023 |
Form of TELA Bio, Inc. Inducement Award Agreement for Non-Qualified Stock Option (filed herewith). EX-10.16 4 tela-20221231xex10d16.htm EX-10.16 Exhibit 10.16 TELA BIO, INC. INDUCEMENT AWARD AGREEMENT FOR NON-QUALIFIED STOCK OPTION STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT TELA Bio, Inc., a Delaware corporation (the “Company”) hereby grants to the individual listed below (“Grantee”) a non-qualified stock option to purchase the number of Shares set forth below (the “Option”) as an ind |
|
| March 23, 2023 |
As filed with the United States Securities and Exchange Commission on March 23, 2023 As filed with the United States Securities and Exchange Commission on March 23, 2023 Registration No. |
|
| March 23, 2023 |
Form of TELA Bio, Inc. Inducement Award Agreement for Restricted Stock Unit (filed herewith). Exhibit 10.17 TELA BIO, INC. INDUCEMENT AWARD AGREEMENT FOR RESTRICTED STOCK UNIT RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT TELA Bio, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) an award of the number of Restricted Stock Units set forth below (the “Restricted Stock Units”) as an inducement to the Participan |
|
| March 23, 2023 |
Exhibit 99.1 TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery Company continues design advancements of biologic-based materials for soft tissue repair and reinforcement MALVERN, PA March 23, 2023 – TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize cli |
|
| March 21, 2023 |
INVESTOR PRESENTATION March 2023 Exhibit 99.2 INVESTOR PRESENTATION March 2023 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, business |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 21, 2023 |
TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results MALVERN, PA, March 21, 2023 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results |
|
| February 21, 2023 |
Exhibit 99.1 TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques Company continues to expand innovative product portfolio to address surgeon needs MALVERN, PA February 21, 2023 – TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative t |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 15, 2023 |
TELA / TELA Bio Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 TELA Bio, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 872381108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 14, 2023 |
TELA / TELA Bio Inc / RTW INVESTMENTS, LP - TELA BIO, INC. Passive Investment SC 13G/A 1 p23-0637sc13ga.htm TELA BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* TELA Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 872381108 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropri |
|
| January 10, 2023 |
INVESTOR PRESENTATION January 2023 Exhibit 99.1 INVESTOR PRESENTATION January 2023 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, busine |
|
| January 10, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 9, 2023 |
Exhibit 99.1 TELA Bio Announces U.S. Commercial Launch of NIVISTM Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds Company grows product portfolio, expanding product offerings to optimize soft tissue preservation and restoration MALVERN, PA January 9, 2023 – TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on provid |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2022 |
TELA Bio Reports Third Quarter 2022 Financial Results Exhibit 99.1 TELA Bio Reports Third Quarter 2022 Financial Results MALVERN, PA, November 9, 2022 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the third |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39130 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 9, 2022 |
INVESTOR PRESENTATION November 2022 Exhibit 99.2 INVESTOR PRESENTATION November 2022 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, busin |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 26, 2022 |
Exhibit 99.1 TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair Study results show a low 2.6% recurrence rate and clinically meaningful improvement in patient quality of life MALVERN, PA, October 26, 2022 – TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovat |
|
| August 24, 2022 |
TELA / TELA Bio Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TELA Bio, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 872381108 (CUSIP Number) August 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ? Rule 13d |
|
| August 22, 2022 |
Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D/A relating to the Common Stock of TELA Bio, Inc. |
|
| August 22, 2022 |
TELA / TELA Bio Inc / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Fund 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and T |
|
| August 19, 2022 |
TELA / TELA Bio Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment SC 13D/A 1 ss1263923sc13da.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* TELA Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 872381108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telepho |
|
| August 19, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 18, 2022 (the ?Statement?), with respect to the ordinary shares of TELA Bio, Inc. |
|
| August 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 17, 2022 |
EX-1.1 2 tm2223653d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version 4,000,000 Shares TELA Bio, Inc. Common Stock UNDERWRITING AGREEMENT August 15, 2022 LAKE STREET CAPITAL MARKETS, LLC LAKE STREET CAPITAL MARKETS, LLC 920 Second Avenue South Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introductory. TELA Bio, Inc., a Delaware corporation (the “Company”), proposes to issue and s |
|
| August 17, 2022 |
4,000,000 Shares TELA Bio, Inc. Common Stock TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(5)? ?Registration No. 333-251505? PROSPECTUS SUPPLEMENT (To Prospectus dated December 29, 2020) 4,000,000 Shares TELA Bio, Inc. Common Stock We are offering 4,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?TELA.? On August 12, 2022, the last reported sale price of our common stock on The |
|
| August 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 15, 2022 |
SUBJECT TO COMPLETION, DATED AUGUST 15, 2022. TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| August 15, 2022 |
INVESTOR PRESENTATION August 2022 Exhibit 99.1 INVESTOR PRESENTATION August 2022 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future res ults of operations, busines |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 10, 2022 |
TELA Bio Reports Second Quarter 2022 Financial Results Exhibit 99.1 TELA Bio Reports Second Quarter 2022 Financial Results MALVERN, PA, August 10, 2022 - TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the secon |
|
| July 18, 2022 |
TELA / TELA Bio Inc / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Fund 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and T |
|
| July 18, 2022 |
Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D/A relating to the Common Stock of TELA Bio, Inc. |
|
| June 23, 2022 |
TELA / TELA Bio Inc / Quaker BioVentures II LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Brian Schwenk Quaker BioVentures II, L.P. 150 Monument Road, Suite 207 Bala Cynwyd, Pennsylvania 19004 (215) 988-6800 (Name, Address and Telephone Number of Person Aut |
|
| June 10, 2022 |
TELA / TELA Bio Inc / Opaleye Management Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. N/A) Tela Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 872381108 (CUSIP Number) James Silverman, One Boston Place, 26th Fl. Boston MA 02108, 617-229-5085 (Name, Address and Telephone Number of Person Auth |
|
| June 3, 2022 |
TELA / TELA Bio Inc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tela Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 872381108 (CUSIP Number) James Silverman, One Boston Place, 26th Fl. Boston MA 02108, 617-229-5085 (Name, Address and Telephone Number of Person Author |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 1, 2022 |
TELA / TELA Bio Inc / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and Telephone Numbe |
|
| June 1, 2022 |
Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D/A relating to the Common Stock of TELA Bio, Inc. |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 31, 2022 |
Exhibit 10.1 Execution Version CREDIT AND SECURITY AGREEMENT dated as of May 26, 2022 by and among TELA BIO, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent, and THE LENDERS FROM TIME TO TIME PARTY HERETO Table of Contents Page Article 1 - DEFINITIONS 1 Section 1.1 Certain Defined Terms 1 S |
|
| May 11, 2022 |
TELA Bio, Inc. Amended and Restated Non-Employee Director Compensation Policy (filed herewith). Exhibit 10.3 ? AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Non-employee members of the board of directors (the ?Board?) of TELA Bio, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compensation described in this Policy shall be p |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2022 |
Exhibit 10.2 ? TELA BIO, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN ? RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT TELA Bio, Inc., a Delaware corporation (the ?Company?), pursuant to its Amended and Restated 2019 Equity Incentive Plan (the ?Plan?), hereby grants to the individual listed below (?Participant?) an award of the number of Restricted Stock Units set f |
|
| May 11, 2022 |
Exhibit 10.1 AMENDED AND RESTATED TELA BIO, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT TELA Bio, Inc., a Delaware corporation (the ?Company?), pursuant to its Amended and Restated 2019 Equity Incentive Plan, as amended from time to time (the ?Plan?), hereby grants to the individual listed below (?Participant?) an option to purchase the number of Shares set |
|
| May 10, 2022 |
TELA Bio Reports First Quarter 2022 Financial Results Exhibit 99.1 TELA Bio Reports First Quarter 2022 Financial Results MALVERN, PA, May 10, 2022 - TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the first quarter |
|
| May 10, 2022 |
A Soft - Tissue Preservation and Restoration Company Investor Presentation May 2022 Exhibit 99.2 A Soft - Tissue Preservation and Restoration Company Investor Presentation May 2022 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 21, 2022 |
DEFA14A 1 tm223563d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 21, 2022 |
Definitive Proxy Statement on Form DEF 14-A, filed on April 21, 2022; TABLE OF CONTENTS United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| March 23, 2022 |
? Exhibit 10.19 ? EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), dated as of September 15, 2020, is made and entered into by and between TELA Bio, Inc., a Delaware corporation (the ?Company?), and Paul Talmo (the ?Executive?). WHEREAS, the Company and Executive desire to continue the employment of Executive with the Company, on the terms and conditions set forth herein. NOW, THE |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) TELA Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value pe |
|
| March 23, 2022 |
Subsidiaries of the Registrant (filed herewith). Exhibit 21.1 LIST OF SUBSIDIARIES ? ? ? Jurisdiction of Incorporation or Subsidiary ? Ownership Percentage ? Organization TELA Bio, Limited ? 100% ? England and Wales ? |
|
| March 23, 2022 |
As filed with the United States Securities and Exchange Commission on March 23, 2022 As filed with the United States Securities and Exchange Commission on March 23, 2022 Registration No. |
|
| March 23, 2022 |
TELA Bio, Inc. Amended and Restated Non-Employee Director Compensation Policy (filed herewith). ? Exhibit 10.14 ? AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Non-employee members of the board of directors (the ?Board?) of TELA Bio, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compensation described in this Policy shall b |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 21, 2022 |
TELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 TELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results MALVERN, PA, March 21, 2022 - TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient?s own anatomy, today reported financi |
|
| March 21, 2022 |
Advancing Soft Tissue Reconstruction Investor Presentation March 2022 Exhibit 99.2 Advancing Soft Tissue Reconstruction Investor Presentation March 2022 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed |
|
| March 3, 2022 |
Exhibit 99.1 TELA Bio Announces U.S. Commercial Launch of SiteGuardTM No Rinse Antimicrobial Solution Company expands product portfolio with focus on addressing surgical site infections in plastic reconstructive surgery MALVERN, PA March 3, 2022 ? TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that o |
|
| March 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 28, 2022 |
Page 14 of 15 Pages Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D/A relating to the Common Stock of TELA Bio, Inc. |
|
| February 28, 2022 |
TELA / TELA Bio Inc / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and Telephone Numbe |
|
| February 14, 2022 |
TELA / TELA Bio Inc / Quaker BioVentures II LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Brian Schwenk Quaker BioVentures II, L.P. 150 Monument Road, Suite 207 Bala Cynwyd, Pennsylvania 19004 (215) 988-6800 (Name, Address and Telephone Number of Person Aut |
|
| February 14, 2022 |
TELA / TELA Bio Inc / RTW INVESTMENTS, LP - TELA BIO, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* TELA Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 872381108 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 19, 2022 |
TELA / TELA Bio Inc / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and Teleph |
|
| January 19, 2022 |
Exhibit 99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D/A relating to the Common Stock of TELA Bio, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2022 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 10, 2021 |
Advancing Soft Tissue Reconstruction Investor Presentation November 2021 EX-99.2 3 tm2132254d2ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Advancing Soft Tissue Reconstruction Investor Presentation November 2021 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limi |
|
| November 10, 2021 |
Exhibit 99.1 TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand MALVERN, Pa., November 10, 2021 (GLOBE NEWSWIRE) - TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, |
|
| November 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 9, 2021 |
Exhibit 99.1 TELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 months ? 12-month follow-up data in 75 patients treated with OviTex? Reinforced Tissue Matrix (RTM) for ventral hernia repair demonstrates an overall hernia recurrence rate of 2.7%. ? Final 24-month analysis shows hernia recurrence rate remains below 5%. MALVERN, PA Nove |
|
| November 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 1, 2021 |
Exhibit 99.1 TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Reconstructive Market for Advanced Anti-Biofilm Surgical Wash Agreement includes exclusive right to sell and market Next Science's proprietary no rinse antimicrobial solution in the US and first right of negotiation for EU market upon CE Approval. MALVERN, PA, November 1, 2021 - TELA Bio, Inc. ("TELA" |
|
| September 27, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), dated August 27, 2021, is made and entered into by and between TELA BIO, INC., a Delaware corporation (the ?Company?), and ROBERTO CUCA (the ?Executive?). WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set forth herein. NOW, THEREFORE, i |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File |
|
| September 21, 2021 |
TELA / TELA Bio Inc / EW HEALTHCARE PARTNERS FUND 2, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Fund 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and T |
|
| September 21, 2021 |
Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D/A relating to the Common Stock of TELA Bio, Inc. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2021 |
Advancing Soft Tissue Reconstruction Investor Presentation August 2021 Exhibit 99.2 Advancing Soft Tissue Reconstruction Investor Presentation August 2021 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed |
|
| August 11, 2021 |
TELA Bio Reports Record Second Quarter 2021 Revenues Driven by Increased Demand Exhibit 99.1 TELA Bio Reports Record Second Quarter 2021 Revenues Driven by Increased Demand MALVERN, Pa., August 11, 2021 (GLOBE NEWSWIRE) - TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported second quarte |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 19, 2021 |
TELA Bio Initiates BRAVO II Study of OviTex® for the Robotic Repair of Ventral Hernias Exhibit 99.1 TELA Bio Initiates BRAVO II Study of OviTex? for the Robotic Repair of Ventral Hernias MALVERN, PA, May 19, 2021 - TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today launched the company's second post-market study, BR |
|
| May 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 18, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and Teleph |
|
| May 18, 2021 |
Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D/A relating to the Common Stock of TELA Bio, Inc. |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2021 |
TELA Bio Announces First Quarter 2021 Financial Results Exhibit 99.1 TELA Bio Announces First Quarter 2021 Financial Results MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) - TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the first quarter |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2021 |
Advancing Soft Tissue Reconstruction Investor Presentation May 2021 Exhibit 99.2 Advancing Soft Tissue Reconstruction Investor Presentation May 2021 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed fu |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37526 45-5320061 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 22, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2021 TELA Bio, Inc. |
|
| April 22, 2021 |
DEFA14A 1 tm212633d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 TELA Bio, Inc. |
|
| March 29, 2021 |
Exhibit 99.1 Advancing Soft Tissue Reconstruction Investor Presentation January 2021 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed f |
|
| March 25, 2021 |
EX-10.29 4 tela-20201231ex1029d9875.htm EX-10.29 Exhibit 10.29 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is made this 22nd day of December, 2020 (the “Effective Date”), by and between WPT LAND 2 LP, a Delaware limited partnership (“Landlord”), and TELA BIO, INC., a Delaware corporation (“Tenant”). BACKGROUND: A. Landlord (pursuant to that c |
|
| March 25, 2021 |
Subsidiaries of the Registrant (filed herewith). Exhibit 21.1 LIST OF SUBSIDIARIES ? ? ? Jurisdiction of Incorporation or Subsidiary ? Ownership Percentage ? Organization TELA Bio, Limited ? 100% ? England and Wales ? |
|
| March 25, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 25, 2021 |
Exhibit 10.11 ? AMENDED AND RESTATED TELA BIO, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT TELA Bio, Inc., a Delaware corporation (the ?Company?), pursuant to its Amended and Restated 2019 Equity Incentive Plan, as amended from time to time (the ?Plan?), hereby grants to the individual listed below (?Participant?) an option to purchase the number of Shares |
|
| March 25, 2021 |
Exhibit 10.12 ? TELA BIO, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN ? RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT TELA Bio, Inc., a Delaware corporation (the ?Company?), pursuant to its Amended and Restated 2019 Equity Incentive Plan (the ?Plan?), hereby grants to the individual listed below (?Participant?) an award of the number of Restricted Stock Units set |
|
| March 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 TELA Bio, Inc. |
|
| March 24, 2021 |
TELA Bio Announces Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 TELA Bio Announces Fourth Quarter and Full Year 2020 Financial Results MALVERN, Pa., March 24, 2021 - TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the fourth quarter and full year |
|
| February 18, 2021 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. N/A) TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Fund 2, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address and T |
|
| February 18, 2021 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to the Common Stock of Tela Bio, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and ( |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 26, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TELA Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 872381108 (CUSIP Number) Brian Schwenk Quaker BioVentures II, L.P. 150 Monument Road, Suite 207 Bala Cynwyd, Pennsylvania 19004 (215) 988-6800 (Name, Address and Telephone Number of Person Aut |
|
| January 26, 2021 |
Exhibit 1 JOINT FILING AGREEMENT Joint Filing Agreement, dated as of February 14, 2020, is by and among Quaker BioVentures II, L. |
|
| January 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 TELA Bio, Inc. |
|
| January 14, 2021 |
TELA Bio Reports Preliminary Results for Fourth Quarter and Full Year 2020 Exhibit 99.1 TELA Bio Reports Preliminary Results for Fourth Quarter and Full Year 2020 MALVERN, Pa., January 14, 2021 (GLOBE NEWSWIRE) - TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported preliminary |
